Cargando…
JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Treatment-Naïve Patients
Multiple sclerosis (MS) treatment with new agents is associated with the risk of the development of progressive multifocal leukoencephalopathy (PML). The seropositivity and a high index of anti-John Cunningham virus (JCV) antibodies are some of the risk factors for PML development. The aim of this s...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759948/ https://www.ncbi.nlm.nih.gov/pubmed/33261210 http://dx.doi.org/10.3390/jcm9123867 |
_version_ | 1783627217304027136 |
---|---|
author | Bonek, Robert Guenter, Wojciech Jałowiński, Robert Karbicka, Anna Litwin, Anna Maciejowski, Maciej Zajdel, Radosław Petit, Veronique Rejdak, Konrad |
author_facet | Bonek, Robert Guenter, Wojciech Jałowiński, Robert Karbicka, Anna Litwin, Anna Maciejowski, Maciej Zajdel, Radosław Petit, Veronique Rejdak, Konrad |
author_sort | Bonek, Robert |
collection | PubMed |
description | Multiple sclerosis (MS) treatment with new agents is associated with the risk of the development of progressive multifocal leukoencephalopathy (PML). The seropositivity and a high index of anti-John Cunningham virus (JCV) antibodies are some of the risk factors for PML development. The aim of this study was to assess the seroprevalence of anti-JCVAb and JCVAb index (AI), as well as its correlations with demographic and clinical characteristics in treatment-naïve Polish MS patients. This is a multicenter, prospective, and cross-sectional study involving 665 MS patients. The overall prevalence of anti-JCVAb was 65.3%, while 63.1% of seropositive patients had an index level of >1.5. The seroprevalence was shown to increase along with the patient’s age. Except for age, the prevalence of anti-JCVAb was not associated with demographic or clinical data. No correlations between the index levels and the demographic or clinical data were observed. In Poland, the seroprevalence of anti-JCVAb in treatment-naïve MS patients is one of the highest in Europe. The majority of seropositive patients had an anti-JCV antibody level denoting a high-risk category. This means that we need further studies to be conducted on the individualization of MS treatment in order to provide patients with an appropriate therapeutic safety level. |
format | Online Article Text |
id | pubmed-7759948 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77599482020-12-26 JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Treatment-Naïve Patients Bonek, Robert Guenter, Wojciech Jałowiński, Robert Karbicka, Anna Litwin, Anna Maciejowski, Maciej Zajdel, Radosław Petit, Veronique Rejdak, Konrad J Clin Med Article Multiple sclerosis (MS) treatment with new agents is associated with the risk of the development of progressive multifocal leukoencephalopathy (PML). The seropositivity and a high index of anti-John Cunningham virus (JCV) antibodies are some of the risk factors for PML development. The aim of this study was to assess the seroprevalence of anti-JCVAb and JCVAb index (AI), as well as its correlations with demographic and clinical characteristics in treatment-naïve Polish MS patients. This is a multicenter, prospective, and cross-sectional study involving 665 MS patients. The overall prevalence of anti-JCVAb was 65.3%, while 63.1% of seropositive patients had an index level of >1.5. The seroprevalence was shown to increase along with the patient’s age. Except for age, the prevalence of anti-JCVAb was not associated with demographic or clinical data. No correlations between the index levels and the demographic or clinical data were observed. In Poland, the seroprevalence of anti-JCVAb in treatment-naïve MS patients is one of the highest in Europe. The majority of seropositive patients had an anti-JCV antibody level denoting a high-risk category. This means that we need further studies to be conducted on the individualization of MS treatment in order to provide patients with an appropriate therapeutic safety level. MDPI 2020-11-27 /pmc/articles/PMC7759948/ /pubmed/33261210 http://dx.doi.org/10.3390/jcm9123867 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bonek, Robert Guenter, Wojciech Jałowiński, Robert Karbicka, Anna Litwin, Anna Maciejowski, Maciej Zajdel, Radosław Petit, Veronique Rejdak, Konrad JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Treatment-Naïve Patients |
title | JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Treatment-Naïve Patients |
title_full | JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Treatment-Naïve Patients |
title_fullStr | JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Treatment-Naïve Patients |
title_full_unstemmed | JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Treatment-Naïve Patients |
title_short | JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Treatment-Naïve Patients |
title_sort | jc virus seroprevalence and jcvab index in polish multiple sclerosis treatment-naïve patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759948/ https://www.ncbi.nlm.nih.gov/pubmed/33261210 http://dx.doi.org/10.3390/jcm9123867 |
work_keys_str_mv | AT bonekrobert jcvirusseroprevalenceandjcvabindexinpolishmultiplesclerosistreatmentnaivepatients AT guenterwojciech jcvirusseroprevalenceandjcvabindexinpolishmultiplesclerosistreatmentnaivepatients AT jałowinskirobert jcvirusseroprevalenceandjcvabindexinpolishmultiplesclerosistreatmentnaivepatients AT karbickaanna jcvirusseroprevalenceandjcvabindexinpolishmultiplesclerosistreatmentnaivepatients AT litwinanna jcvirusseroprevalenceandjcvabindexinpolishmultiplesclerosistreatmentnaivepatients AT maciejowskimaciej jcvirusseroprevalenceandjcvabindexinpolishmultiplesclerosistreatmentnaivepatients AT zajdelradosław jcvirusseroprevalenceandjcvabindexinpolishmultiplesclerosistreatmentnaivepatients AT petitveronique jcvirusseroprevalenceandjcvabindexinpolishmultiplesclerosistreatmentnaivepatients AT rejdakkonrad jcvirusseroprevalenceandjcvabindexinpolishmultiplesclerosistreatmentnaivepatients |